Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL3593648 | 0.94 | SQOR (0.46) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3595104 | 0.92 | SQOR (0.46) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3593650 | 0.86 | SQOR (0.43) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3583516 | 0.83 | SQOR (0.46) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3592445 | 0.82 | SQOR (0.47) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3580685 | 0.81 | PDE5A (0.48) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3590309 | 0.79 | SQOR (0.44) | SQORALDH1A1HPGD | |
| SCHEMBL3585039 | 0.78 | SQOR (0.46) | SQORKDM4EHPGDMAPTSMN1; SMN2 | |
| Tromethamine SCHEMBL3584251 | 0.78 | SQOR (0.43) | SQORKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL13545945 | 0.76 | SQOR (0.42) | SQORLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| WO-2007124546-A1 | INTEGRASE INHIBITORS 3 | AVEXA LIMITED (AU) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | TYMP, IMPDH1, IMPDH2 | SQOR 3669/4885KDM4E 1075/4885ALDH1A1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.